RaQualia Pharma Inc. provided consolidated earnings guidance for the year ending December 31, 2023. For the year ending December 31, 2023, the company expects net sales of JPY 2,799 million, operating profit of JPY 260 million and profit attributable to owners of parent of JPY 183 million or JPY 8.74 per basic share.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
595 JPY | 0.00% | -2.46% | -13.66% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.66% | 82.11M | |
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B |
- Stock Market
- Equities
- 4579 Stock
- News RaQualia Pharma Inc.
- RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023